These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22200908)

  • 1. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
    Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
    Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.
    Knops E; Däumer M; Awerkiew S; Kartashev V; Schülter E; Kutsev S; Brakier-Gingras L; Kaiser R; Pfister H; Verheyen J
    J Antimicrob Chemother; 2010 Jul; 65(7):1472-6. PubMed ID: 20430786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
    van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
    Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
    Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
    AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
    Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
    J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
    Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
    PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
    Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
    PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
    Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
    Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
    Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.
    Myint L; Matsuda M; Matsuda Z; Yokomaku Y; Chiba T; Okano A; Yamada K; Sugiura W
    Antimicrob Agents Chemother; 2004 Feb; 48(2):444-52. PubMed ID: 14742193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 protease-substrate coevolution in nelfinavir resistance.
    Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
    J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease.
    Flynn WF; Chang MW; Tan Z; Oliveira G; Yuan J; Okulicz JF; Torbett BE; Levy RM
    PLoS Comput Biol; 2015 Apr; 11(4):e1004249. PubMed ID: 25894830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.